Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why ZIOPHARM Oncology Inc. Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ZIOPHARM Oncology (NASDAQ: ZIOP  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer, jumped as much as 17% after announcing the results of preclinical and clinical activity for investigational compound Ad-RTS-IL-12 in an oral presentation at the American Society of Gene and Cell Therapy's annual meeting in Washington D.C.

So what: According to ZIOPHARM's press release, IL-12 gene expression levels can be controlled using Intrexon's (NYSE: XON  ) RheoSwitch Therapeutic System to essentially "switch on" IL-12 expression and lead to powerful anti-tumor and anti-cancer stem cell effects. As noted, "This immune response is characterized by an increase in tumor infiltrating lymphocytes with system wide immune activation." ZIOPHARM noted positive anti-tumor effects in both phase 1 and 2 for Ad-RTS-IL-12 patients with breast cancer and melanoma in its presentation, as well as a potent anti-cancer effect in a glioma model which demonstrated tumor mass shrinkage and prolonged survival compared to the current standard of treatment. Most importantly, the data showed a reduction in brain cancer stem cells which are believed to be the primary cause of relapse or metastasis.

Now what: As always, keep in mind that these are very early stage results and it's probably not worth getting too excited until we have some tangible efficacy results in a larger pool of patients (i.e., phase 2 studies). I wouldn't, however, fault you for putting ZIOPHARM on your watchlist given that anti-cancer stem cell research is drawing a lot of investments from big pharma. Anti-cancer stem cell therapies also represent one of the first attempts to treat cancer at the source rather than simply trying to manage its proliferation. Today's data is intriguing for sure, but I believe ZIOPHARM is still a volatile and dangerous investment considering that it's wholly clinical-stage and burning through its remaining cash.

ZIOPHARM shares may have soared today, but they'll likely struggle to keep pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2970288, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:22:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,532.10 180.72 1.11%
S&P 500 1,972.30 23.44 1.20%
NASD 4,795.91 45.93 0.97%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 11:06 AM
ZIOP $9.13 Up +0.05 +0.55%
ZIOPHARM Oncology CAPS Rating: **
XON $42.90 Down -0.10 -0.23%